<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Molecular and Cellular Medicine</title>
<title_fa>مجله بین المللی سلولی و مولکولی</title_fa>
<short_title>Int J Mol Cell Med</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijmcmed.org</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2251-9637</journal_id_issn>
<journal_id_issn_online>2251-9645</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.22088/IJMCM.BUMS</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1399</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2021</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>10</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Knockdown of SOX12 Expression Induced Apoptotic Factors is Associated with TWIST1 and CTNNB1 Expression in Human Acute Myeloid Leukemia Cells</title>
	<subject_fa>Hematology</subject_fa>
	<subject>Hematology</subject>
	<content_type_fa>Original Article</content_type_fa>
	<content_type>Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>Recent improvements in molecular treatment and gene therapy led to discovering novel cancer remedies. Antisense LNA GapmeRs is a state-of-the-art molecular research field for diagnosing and treating various cancer types. Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy defined by the rapid accumulation and malignant proliferation of immature myeloid progenitors. &lt;em&gt;SOX12&lt;/em&gt;&amp;nbsp;is a new potential target for acute myeloid leukemia.&amp;nbsp; In this study, &lt;em&gt;SOX12&amp;nbsp;&lt;/em&gt;was blocked by antisense LNA GapmeRs (ALG) in human AML cell lines (KG1 and M07e). Cells were transfected with Gapmer anti-&lt;em&gt;SOX12&lt;/em&gt; at 24, 48, and 72 h post-transfection. Transfection efficiency was assessed by a fluorescent microscope. Furthermore, evaluation of &lt;em&gt;SOX12&lt;/em&gt;,&lt;em&gt; TWIST1&lt;/em&gt;,&lt;em&gt; CTNNB1&lt;/em&gt;,&lt;em&gt; CASP3&lt;/em&gt;, and&lt;em&gt; CASP9 &lt;/em&gt;expression was performed by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Cell viability was determined by MTT assay. &lt;em&gt;SOX12&amp;nbsp;&lt;/em&gt;expression was decreased remarkably in the ALG group. Moreover, &lt;em&gt;SOX12&lt;/em&gt; knockdown was associated with a decrease in &lt;em&gt;TWIST1&lt;/em&gt; and &lt;em&gt;CTNNB1&lt;/em&gt; expression. Besides, downregulation of &lt;em&gt;SOX12 &lt;/em&gt;in both cell lines could induce apoptosis, probably through upregulation of &lt;em&gt;CASP3&lt;/em&gt; and &lt;em&gt;CASP9&lt;/em&gt;. The findings reveal that &lt;em&gt;SOX12&lt;/em&gt; knockdown could be a new target for reducing AML cells proliferation through antisense therapy approach.</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Acute myeloblastic leukemia, antisense LNA GapmeRs, SOX12, TWIST1, CTNNB1, apoptosis</keyword>
	<start_page>249</start_page>
	<end_page>257</end_page>
	<web_url>http://ijmcmed.org/browse.php?a_code=A-10-1083-2&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Arezou</first_name>
	<middle_name></middle_name>
	<last_name>Dabiri</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>Arezou.dabiri@gmail.com</email>
	<code>100319475328460023508</code>
	<orcid>100319475328460023508</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mohammadreza</first_name>
	<middle_name></middle_name>
	<last_name>Sharifi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mo_sharifi@med.mui.ac.ir</email>
	<code>100319475328460023509</code>
	<orcid>100319475328460023509</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Akram</first_name>
	<middle_name></middle_name>
	<last_name>Sarmadi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>akramsarmadi@gmail.com</email>
	<code>100319475328460023510</code>
	<orcid>100319475328460023510</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
